ორშაბათი, აპრილი 13, 2026
- Advertisement -
Google search engine
Global Ingredient Risk Index Specialty

Dried Fig Powder

Ficus carica

Also known as: Fig fruit powder, Ficus carica powder, Dried fig, Fig fiber

LOW RISK 1.0/10 How?

This ingredient is classified as unclassified risk (GIRI score: 1.0/10).

02

Safety Profile

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
03

Interactions

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
04

Evidence and Scientific Findings

Overview

Ingredient Overview

Dried fig powder is a concentrated food ingredient providing pectin, iron, calcium, and potassium with mild laxative properties. It has an excellent safety record as a food. High sugar content is relevant for diabetic individuals. The natural latex content in some fig preparations may cause oral allergy syndrome in latex-sensitive individuals. No significant drug interactions at supplemental doses.

Classification

Biological and Chemical Classification

Scientific Name
Ficus carica
Mechanism

Mechanism of Action

Information not yet available for this ingredient profile.

Clinical Evidence

Clinical Evidence of Effectiveness

Information not yet available for this ingredient profile.

Pharmacokinetics

Pharmacokinetics

Information not yet available for this ingredient profile.

Dosage

Recommended Dosage

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
05

SETI — Scientific Evidence Transparency Index

SETI Score 50/100
Risk Level High risk
Scientific Confidence Low
Evidence Strength Limited
Key Benefit Specialty
Evidence Reviewed 10 PubMed studies
Scientific Confidence Low
Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100
Risk Level High risk
Evidence Strength Limited
Main Benefit Specialty
Ingredient Dried Fig Powder
Scientific name Ficus carica
Scientific Evidence Overview
  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or RCT)
  • Main clinical benefit observed: Specialty
  • Evidence consistency: High consistency across studies (100%)
Safety Signals
  • No significant safety signals identified in the reviewed literature.
Evidence Strength Limited
Final Scientific Assessment

The available scientific evidence for Dried Fig Powder indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Dried Fig Powder
Evidence reviewed 10 peer-reviewed studies (last 10 years)
Scientific name Ficus carica
50 /100

Total SETI Score

High risk
Evidence quality 10/40
Evidence consistency 20/20
Safety signals 0/20
Study recency 10/10
Evidence transparency 10/10

Evidence Summary

  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or systematic review)
  • 0 studies identified benefits or no safety concern (GREEN)
  • 10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 06 აპრ 2026, 12:10

Evidence Distribution

10 Other / unclassified
  1. Observational / other LOW evidence YELLOW
    Effects of saturation flash protocols on photosynthetic induction and assessment of mesophyll conductance and maximum carboxylation rate sensitivity to parameter inputs in… ↗
    PMID 41923936 ↗
    Journal Front Plant Sci
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41923936/
    Jin W et al.. Effects of saturation flash protocols on photosynthetic induction and assessment of mesophyll conductance and maximum carboxylation rate sensitivity to parameter inputs in Ficus carica.. Front Plant Sci. 2026. PMID:41923936.
  2. Observational / other LOW evidence YELLOW
    The Black Fig Fly, Silba adipata (Diptera: Lonchaeidae): Current Knowledge and Future Research Needs for an Invasive Pest of Fig Production. ↗
    PMID 41898909 ↗
    Journal Insects
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41898909/
    Lasa R et al.. The Black Fig Fly, Silba adipata (Diptera: Lonchaeidae): Current Knowledge and Future Research Needs for an Invasive Pest of Fig Production.. Insects. 2026. PMID:41898909.
  3. Observational / other LOW evidence YELLOW
    Pathogen Identification and Pathogenicity of Fig (Ficus carica L.) Branch Canker Disease in Kashi, Xinjiang. ↗
    PMID 41893095 ↗
    Journal J Fungi (Basel)
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41893095/
    Xie P et al.. Pathogen Identification and Pathogenicity of Fig (Ficus carica L.) Branch Canker Disease in Kashi, Xinjiang.. J Fungi (Basel). 2026. PMID:41893095.
  4. Observational / other LOW evidence YELLOW
    FcMAPK4-phosphorylated FcNOR activates FcERF5 to promote fig fruit softening through activation of FcPG12 expression. ↗
    PMID 41872729 ↗
    Journal J Integr Plant Biol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41872729/
    Wang Y et al.. FcMAPK4-phosphorylated FcNOR activates FcERF5 to promote fig fruit softening through activation of FcPG12 expression.. J Integr Plant Biol. 2026. PMID:41872729.
  5. Observational / other LOW evidence YELLOW
    Comparative Effects of Agastache rugosa Extract and a Complex of Agastache rugosa, Ficus carica, and Lycium barbarum Extracts on Skin Aging: A… ↗
    PMID 41817298 ↗
    Journal J Med Food
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41817298/
    Cho Y et al.. Comparative Effects of Agastache rugosa Extract and a Complex of Agastache rugosa, Ficus carica, and Lycium barbarum Extracts on Skin Aging: A Randomized, Double-Blind, Placebo-Controlled Trial.. J Med Food. 2026. PMID:41817298.
  6. Observational / other LOW evidence YELLOW
    Investu0131gatu0131on of the In vitro and In vivo effect of a mixture of Ficus carica L. and Hippophae rhamnoides L. on experu0131mentally… ↗
    PMID 41793960 ↗
    Journal Burns
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41793960/
    Bayrakceken HU et al.. Investu0131gatu0131on of the In vitro and In vivo effect of a mixture of Ficus carica L. and Hippophae rhamnoides L. on experu0131mentally induced burns in rats.. Burns. 2026. PMID:41793960.
  7. Observational / other LOW evidence YELLOW
    Genome sequence of Gilbertella persicaria strain SHK1000 isolated from fig fruit. ↗
    PMID 41789913 ↗
    Journal Microbiol Resour Announc
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41789913/
    Nakano M. Genome sequence of Gilbertella persicaria strain SHK1000 isolated from fig fruit.. Microbiol Resour Announc. 2026. PMID:41789913.
  8. Observational / other LOW evidence YELLOW
    New insight on the assessment of potassium silicate on pharmaceutical, morphological, and elemental status of Ficus carica: in vitro. ↗
    PMID 41787484 ↗
    Journal BMC Res Notes
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41787484/
    Abou-Baker NH et al.. New insight on the assessment of potassium silicate on pharmaceutical, morphological, and elemental status of Ficus carica: in vitro.. BMC Res Notes. 2026. PMID:41787484.
  9. Observational / other LOW evidence YELLOW
    Salubrious effects of Ficus carica L. leaves extract in inflammation, diabetes, and obesity: An in-vitro, in-silico, and in-vivo study. ↗
    PMID 41777240 ↗
    Journal Food Nutr Res
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41777240/
    Hasnain SZU et al.. Salubrious effects of Ficus carica L. leaves extract in inflammation, diabetes, and obesity: An in-vitro, in-silico, and in-vivo study.. Food Nutr Res. 2026. PMID:41777240.
  10. Observational / other LOW evidence YELLOW
    Genotype u00d7 Environment Shapes Fig Seed Oil Metabolic Fingerprinting. ↗
    PMID 41745609 ↗
    Journal Metabolites
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41745609/
    Kassimi CE et al.. Genotype u00d7 Environment Shapes Fig Seed Oil Metabolic Fingerprinting.. Metabolites. 2026. PMID:41745609.
═══════════════════════════════════════════════════════════════════════ -->
06

Score Transparency

Q × L × D × S × 10 = 1.0 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

Q
Evidence Quantity 0 / 10
0%

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

L
Evidence Quality 5 / 10
50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

D
Evidence Direction 5 / 10
Benefit
Risk
50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

S
Safety Signals 5 / 10
50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 1.0 / 10

Final GIRI Score for Dried Fig Powder. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

  • References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
  • Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
  • Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
  • Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
07

Risk Level Classification

LOW RISK 1.0/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0
MODERATE
3.0–5.5
HIGH
5.5–7.5
CRITICAL
7.5–10
1.0

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Dried Fig Powder

GIRI Score 1.0 / 10

A score of 1.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Evidence Quantity (Q) 0 / 10 refs

0 approved references.

Evidence Quality (L) 50%

Limited — mostly case reports or animal studies (Level 4–5).

Evidence Direction (D) 50% toward risk

Neutral or mixed — benefit and risk signals roughly balanced.

Safety Signals (S) 0 active signals

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

Regulatory Status No restrictions found

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

LevelScoreMeaning
LOW0.0 – 2.9Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE3.0 – 5.4Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH5.5 – 7.4Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL7.5 – 10Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

ბოლო სიახლეები

პოპულარული ამბები

კატეგორიები

ჩვენ შესახებ

info@accreditation.ge
ჩვენს შესახებ / რეკლამა / კონტაქტი

გამოგვყევი სოციალურ ქსელებში

© SheniEkimi.ge